Ionis Operating Income from 2010 to 2024

IONS Stock

USD 35.73 0.17 0.47%

Ionis Pharmaceuticals Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Ionis Pharmaceuticals generates from its operations. View All Fundamentals

Operating Income

First Reported

1990-03-31

Previous Quarter

-66.1 M

Current Value

-148.7 M

Quarterly Volatility

47.7 M

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.6 M, Interest Expense of 85.5 M or Total Revenue of 827 M, as well as many indicators such as Price To Sales Ratio of 15.6, Dividend Yield of 0.0 or PTB Ratio of 17.8. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Ionis Pharmaceuticals Correlation against competitors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Latest Ionis Pharmaceuticals' Operating Income Growth Pattern

Below is the plot of the Operating Income of Ionis Pharmaceuticals over the last few years. Operating Income is the amount of profit realized from Ionis Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Ionis Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Ionis Pharmaceuticals' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Ionis Operating Income Regression Statistics

	Arithmetic Mean	(89,307,300)
	Coefficient Of Variation	(207.07)
	Mean Deviation	122,072,573
	Median	(61,372,000)
	Standard Deviation	184,932,659
	Sample Variance	34200.1T
	Range	777M
	R-Value	(0.44)
	Mean Square Error	29559.6T
	R-Squared	0.20
	Significance	0.1
	Slope	(18,373,723)
	Total Sum of Squares	478801.2T

Ionis Operating Income History

	2024	-336 M
	2023	-353.7 M
	2022	-411 M
	2021	-30 M
	2020	-172 M
	2019	366 M
	2018	-61.4 M

Other Fundumenentals of Ionis Pharmaceuticals

Non Operating Income Net Other

Ionis Pharmaceuticals Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Net Receivables	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.73	-0.16	-0.6	0.93	1.0	0.3	0.74	0.52	0.5	0.96	0.43	0.86	0.52	0.91	0.83	0.86	0.93	0.0	0.28	0.94	0.95	0.61	-0.48
Total Stockholder Equity	0.73		-0.75	-0.04	0.43	0.7	0.24	0.5	0.18	0.09	0.67	0.32	0.35	0.74	0.57	0.96	0.33	0.76	-0.1	0.24	0.79	0.74	0.01	0.15
Net Debt	-0.16	-0.75		-0.38	0.17	-0.14	-0.09	-0.11	0.09	0.3	-0.1	-0.13	0.17	-0.63	-0.03	-0.57	0.22	-0.27	0.03	-0.12	-0.29	-0.17	0.54	-0.7
Retained Earnings	-0.6	-0.04	-0.38		-0.78	-0.62	-0.27	-0.8	-0.7	-0.47	-0.54	-0.71	-0.74	-0.22	-0.63	-0.1	-0.78	-0.54	-0.27	-0.25	-0.36	-0.42	-0.61	0.59
Total Liab	0.93	0.43	0.17	-0.78		0.94	0.29	0.73	0.58	0.61	0.9	0.4	0.95	0.31	0.88	0.58	0.96	0.84	0.05	0.27	0.82	0.86	0.78	-0.68
Total Current Assets	1.0	0.7	-0.14	-0.62	0.94		0.32	0.75	0.52	0.53	0.95	0.42	0.87	0.52	0.9	0.81	0.87	0.93	0.01	0.3	0.93	0.94	0.63	-0.49
Short Term Debt	0.3	0.24	-0.09	-0.27	0.29	0.32		0.29	0.1	0.33	0.33	0.11	0.07	0.46	0.28	0.26	0.08	0.39	-0.06	1.0	0.27	0.17	0.18	-0.13
Intangible Assets	0.74	0.5	-0.11	-0.8	0.73	0.75	0.29		0.52	0.29	0.64	0.81	0.69	0.59	0.64	0.48	0.71	0.75	0.13	0.28	0.6	0.62	0.33	-0.24
Accounts Payable	0.52	0.18	0.09	-0.7	0.58	0.52	0.1	0.52		0.33	0.47	0.56	0.48	0.19	0.72	0.21	0.52	0.47	0.4	0.09	0.24	0.31	0.36	-0.42
Net Receivables	0.5	0.09	0.3	-0.47	0.61	0.53	0.33	0.29	0.33		0.48	0.04	0.56	0.19	0.5	0.24	0.57	0.47	-0.07	0.32	0.43	0.44	0.56	-0.55
Short Term Investments	0.96	0.67	-0.1	-0.54	0.9	0.95	0.33	0.64	0.47	0.48		0.29	0.81	0.42	0.92	0.79	0.81	0.91	-0.2	0.32	0.9	0.92	0.62	-0.5
Common Stock	0.43	0.32	-0.13	-0.71	0.4	0.42	0.11	0.81	0.56	0.04	0.29		0.36	0.55	0.39	0.21	0.4	0.37	0.28	0.1	0.24	0.24	0.14	-0.1
Long Term Debt	0.86	0.35	0.17	-0.74	0.95	0.87	0.07	0.69	0.48	0.56	0.81	0.36		0.26	0.76	0.48	1.0	0.76	0.02	0.05	0.78	0.82	0.72	-0.59
Property Plant Equipment	0.52	0.74	-0.63	-0.22	0.31	0.52	0.46	0.59	0.19	0.19	0.42	0.55	0.26		0.42	0.62	0.25	0.56	-0.09	0.46	0.54	0.43	-0.08	0.21
Current Deferred Revenue	0.91	0.57	-0.03	-0.63	0.88	0.9	0.28	0.64	0.72	0.5	0.92	0.39	0.76	0.42		0.7	0.77	0.84	0.03	0.26	0.75	0.8	0.6	-0.57
Net Tangible Assets	0.83	0.96	-0.57	-0.1	0.58	0.81	0.26	0.48	0.21	0.24	0.79	0.21	0.48	0.62	0.7		0.46	0.83	-0.12	0.26	0.88	0.86	0.21	-0.08
Long Term Debt Total	0.86	0.33	0.22	-0.78	0.96	0.87	0.08	0.71	0.52	0.57	0.81	0.4	1.0	0.25	0.77	0.46		0.76	0.04	0.06	0.76	0.81	0.76	-0.64
Capital Surpluse	0.93	0.76	-0.27	-0.54	0.84	0.93	0.39	0.75	0.47	0.47	0.91	0.37	0.76	0.56	0.84	0.83	0.76		-0.03	0.38	0.87	0.89	0.37	-0.25
Deferred Long Term Liab	0.0	-0.1	0.03	-0.27	0.05	0.01	-0.06	0.13	0.4	-0.07	-0.2	0.28	0.02	-0.09	0.03	-0.12	0.04	-0.03		-0.07	-0.16	-0.15	0.06	-0.11
Short Long Term Debt	0.28	0.24	-0.12	-0.25	0.27	0.3	1.0	0.28	0.09	0.32	0.32	0.1	0.05	0.46	0.26	0.26	0.06	0.38	-0.07		0.25	0.15	0.14	-0.08
Net Invested Capital	0.94	0.79	-0.29	-0.36	0.82	0.93	0.27	0.6	0.24	0.43	0.9	0.24	0.78	0.54	0.75	0.88	0.76	0.87	-0.16	0.25		0.97	0.54	-0.35
Net Working Capital	0.95	0.74	-0.17	-0.42	0.86	0.94	0.17	0.62	0.31	0.44	0.92	0.24	0.82	0.43	0.8	0.86	0.81	0.89	-0.15	0.15	0.97		0.56	-0.42
Capital Stock	0.61	0.01	0.54	-0.61	0.78	0.63	0.18	0.33	0.36	0.56	0.62	0.14	0.72	-0.08	0.6	0.21	0.76	0.37	0.06	0.14	0.54	0.56		-0.94
Long Term Investments	-0.48	0.15	-0.7	0.59	-0.68	-0.49	-0.13	-0.24	-0.42	-0.55	-0.5	-0.1	-0.59	0.21	-0.57	-0.08	-0.64	-0.25	-0.11	-0.08	-0.35	-0.42	-0.94

Click cells to compare fundamentals

About Ionis Pharmaceuticals Financial Statements

Ionis Pharmaceuticals shareholders use historical fundamental indicators, such as Operating Income, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Ionis Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Ionis Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Operating Income	-353.7 M	-336 M
Non Operating Income Net Other	184.4 M	193.6 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ionis Operating Income from 2010 to 2024

Latest Ionis Pharmaceuticals' Operating Income Growth Pattern

Ionis Operating Income Regression Statistics

Ionis Operating Income History

Other Fundumenentals of Ionis Pharmaceuticals

Ionis Pharmaceuticals Operating Income component correlations

About Ionis Pharmaceuticals Financial Statements

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Ionis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY